Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Using 5% topical minoxidil improved and normalized the hair growth in a girl with short anagen hair naevus.

In this study, 4-(4-(phenylaminocarbonyl)benzoyl) benzoic acid exhibited the strongest inhibitory activity against the human type 2 steroid 5α-reductase isozyme among the compounds tested.

This article outlines the synthesis of spiro[cyclohexane‐1,2′‐[2 H ]indene] derivatives similar to known steroid 5α‐reductase inhibitors, but it does not report experimental findings.

This study suggests that hepatocellular carcinoma in cirrhotic men is associated with altered sex-steroid metabolism, indicated by lower testosterone and 5 alpha-dihydrotestosterone levels compared to cirrhosis alone.

This study reports that pumpkin seed oil-loaded niosomes significantly decreased hair loss and increased hair growth indicators in vivo, suggesting potential as a natural anti-hair loss therapy.

This study found that 5-bromo-3,4-dihydroxybenzaldehyde (BDB) promoted hair growth in rat vibrissa follicles by activating Wnt/β-catenin and autophagy pathways and inhibiting the TGF-β pathway in dermal papilla cells.

This study found that Phyllanthus urinaria extract displayed significant anti-alopecia properties in a mouse model, showing potential as an anti-5α-reductase agent for androgenic hair loss.

This article describes standard methods for studying DNA methylation dynamics in mouse skin and hair follicle stem cells but presents no new research findings.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.

The side gland of Suncus murinus is a good model for studying human sebaceous glands.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

In this study, 5-α reductase inhibitors were not significantly linked to increased rhabdomyolysis risk, but they may raise the risk of myopathy and myositis in men aged 66 and older.

This study found that several compounds from Yangxue Shengfa capsule may promote hair growth by enhancing cell proliferation in vitro, suggesting potential use in treating androgenetic alopecia.

The source does not provide an abstract for this letter to the editor, so specific results regarding the long-term efficacy and safety of dutasteride for male androgenetic alopecia are not reported.

This review found that dutasteride and finasteride are rarely associated with sexual side effects when used off-label for female hair loss, and suggests further study of their efficacy and side effect profile.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

This study reports that 5-alpha-reductase inhibitors do not prevent prostate cancer and merely reduce the likelihood of undergoing diagnostic biopsies, potentially misleading patients and physicians.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

Finasteride reduces prostate size and symptoms with few side effects.

In this study, children with 5-alpha-reductase deficiency and micropenis treated with oral testosterone undecanoate showed increased penile length to a target level after 3-9 months, with no severe adverse effects observed, suggesting the treatment's safety and efficacy.

In this study, the authors reported that dutasteride significantly reduced total remission time for COVID-19 symptoms in men compared to placebo, especially for fatigue and loss of taste or smell.

This study found that combination therapy with LLLT and 5% minoxidil improved hair diameter and density more effectively than each treatment alone in women with female pattern hair loss.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.